

# Robert J Klaassen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5704278/publications.pdf>

Version: 2024-02-01

154  
papers

3,453  
citations

147801

31  
h-index

168389

53  
g-index

157  
all docs

157  
docs citations

157  
times ranked

4227  
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. <i>Blood Advances</i> , 2022, 6, 1844-1853.	5.2	12
2	Poor outcome after hematopoietic stem cell transplantation of patients with unclassified inherited bone marrow failure syndromes. <i>European Journal of Haematology</i> , 2022, 108, 278-287.	2.2	1
3	Novel cysteine substitution p.(Cys1084Tyr) causes variable expressivity of qualitative and quantitative VWF defects. <i>Blood Advances</i> , 2022, , .	5.2	0
4	Integration of Patient-reported Outcome Measures in Pediatric Hematology: A Qualitative Methods Study. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, Publish Ahead of Print, .	0.6	0
5	Patient-Reported Outcomes Measurement in Radiation Oncology: Interpretation of Individual Scores and Change over Time in Clinical Practice. <i>Current Oncology</i> , 2022, 29, 3093-3103.	2.2	5
6	SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29760.	1.5	3
7	Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28974.	1.5	0
8	Updating the Canadian Hemophilia Outcomes "Kids"™ Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 403-411.	2.3	5
9	Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	1.5	4
10	Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H-FIT). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12519.	2.3	1
11	Patterns of joint damage in severe haemophilia A treated with prophylaxis. <i>Haemophilia</i> , 2021, 27, 666-673.	2.1	1
12	Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1407-1417.	1.8	5
13	Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes. <i>Haemophilia</i> , 2021, 27, 751-759.	2.1	9
14	Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening. <i>BMC Pediatrics</i> , 2021, 21, 296.	1.7	1
15	Successful treatment of pediatric primary hepatic Burkitt lymphoma using rituximab: A case report. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29259.	1.5	1
16	Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopenia (ITP) in children: study protocol. <i>BMJ Open</i> , 2021, 11, e044885.	1.9	2
17	Characterization of physical literacy in children with chronic medical conditions compared with healthy controls: a cross-sectional study. <i>Applied Physiology, Nutrition and Metabolism</i> , 2021, 46, 1073-1082.	1.9	7
18	Immune tolerance induction using Fc fusion protein recombinant factor IX in severe haemophilia B. <i>Haemophilia</i> , 2021, 27, e776-e779.	2.1	0

#	ARTICLE	IF	CITATIONS
19	The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12601.	2.3	5
20	Magnetic resonance imaging in boys with severe hemophilia A: Serial and end-of-study findings from the Canadian Hemophilia Primary Prophylaxis Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12565.	2.3	4
21	Patient-reported Outcome Measures in Pediatric Non-Malignant Hematology: A Systematic Review. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, 121-134.	0.6	5
22	Evaluating the Impact of Thrombopoietin Receptor Agonists Medications on Patient Outcomes and Quality of Life in Pediatric Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 4072-4072.	1.4	0
23	Pharmacist Integration into the Hemophilia Treatment Centre: A Canadian Pilot Project to Optimize Treatment and Improve Cost-Savings Using Pharmacokinetic Assessments of Hemophilia Patients. <i>Blood</i> , 2021, 138, 832-832.	1.4	0
24	Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease-specific assessments. <i>European Journal of Haematology</i> , 2020, 104, 427-434.	2.2	9
25	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 191, 98-106.	2.5	18
26	Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry. <i>British Journal of Haematology</i> , 2020, 189, 976-981.	2.5	8
27	Hemophilia prophylaxis adherence and bleeding using a tailored, frequency-escalated approach: The Canadian Hemophilia Primary Prophylaxis Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 318-325.	2.3	16
28	Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 170-174.	0.6	1
29	IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP. <i>Blood Advances</i> , 2020, 4, 1492-1500.	5.2	16
30	Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e107-e109.	0.6	5
31	Cellular and molecular architecture of hematopoietic stem cells and progenitors in genetic models of bone marrow failure. <i>JCI Insight</i> , 2020, 5, .	5.0	6
32	Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
33	Affairs of the heart, does congenital heart disease make you happier?. <i>Archives of Disease in Childhood</i> , 2019, 104, 105-105.	1.9	0
34	Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27709.	1.5	5
35	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	4.1	37
36	Reanalysing genomic data by normalized coverage values uncovers CNVs in bone marrow failure gene panels. <i>Npj Genomic Medicine</i> , 2019, 4, 30.	3.8	3

#	ARTICLE	IF	CITATIONS
37	The social impact of early psychological maturity in adolescents with cancer. <i>Psycho-Oncology</i> , 2019, 28, 586-592.	2.3	11
38	Development of Patient-Reported Outcome Measures (Symptoms and Impacts) in Adults with Pyruvate Kinase Deficiency. <i>Blood</i> , 2019, 134, 3447-3447.	1.4	0
39	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	4.1	30
40	Molecular analysis and genotype-phenotype correlation of Diamond-Blackfan anemia. <i>Clinical Genetics</i> , 2018, 93, 320-328.	2.0	26
41	The burden of disease in pyruvate kinase deficiency: Patients' perception of the impact on health-related quality of life. <i>European Journal of Haematology</i> , 2018, 101, 758-765.	2.2	25
42	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. <i>Lancet Haematology</i> , 2018, 5, e252-e260.	4.6	31
43	Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. <i>Blood</i> , 2018, 132, 448-452.	1.4	16
44	Predictors of Hydroxyurea Use in Children with Sickle Cell Disease. <i>Blood</i> , 2018, 132, 4934-4934.	1.4	0
45	Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. <i>Blood</i> , 2018, 132, 4813-4813.	1.4	1
46	Increasing Incidence and Prevalence of Pathologic Hemoglobinopathies Among Children in Ontario, Canada from 1991-2013. <i>Blood</i> , 2018, 132, 4698-4698.	1.4	3
47	Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26588.	1.5	20
48	Paediatric health-related quality of life: what is it and why should we measure it?. <i>Archives of Disease in Childhood</i> , 2017, 102, 393-400.	1.9	77
49	Patterns and influences in health-related quality of life in children with immune thrombocytopenia: A study from the Dallas ITP Cohort. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26405.	1.5	19
50	Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. <i>Annals of Hematology</i> , 2017, 96, 1937-1944.	1.8	11
51	Severe Neutropenia and Anemia in a Child With Epilepsy and Copper Deficiency on a Ketogenic Diet. <i>Pediatric Neurology</i> , 2017, 76, 93-94.	2.1	8
52	Reply to comment on: Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26763.	1.5	0
53	Pediatric Oncology Clinic Care Model: Achieving Better Continuity of Care for Patients in a Medium-sized Program. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 476-480.	0.6	2
54	The clinical impact of copy number variants in inherited bone marrow failure syndromes. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	10

#	ARTICLE	IF	CITATIONS
55	Quality of life of pediatric oncology patients: Do patient-reported outcome instruments measure what matters to patients?. <i>Quality of Life Research</i> , 2017, 26, 273-281.	3.1	25
56	Health-Related Quality of Life. <i>Pediatric Oncology</i> , 2017, , 735-747.	0.5	3
57	A Prospective Study of the Association Between Clinically Significant Bleeding in PICU Patients and Thrombocytopenia or Prolonged Coagulation Times*. <i>Pediatric Critical Care Medicine</i> , 2017, 18, e455-e462.	0.5	11
58	Case 1: A newborn with pancytopenia. <i>Paediatrics and Child Health</i> , 2016, 21, 9-11.	0.6	0
59	Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer. <i>European Journal of Cancer</i> , 2016, 64, 101-106.	2.8	15
60	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1407-1413.	1.5	70
61	Reply to: Vitamin insufficiencies/deficiencies in relation to sickle cell disease severity and associated morbidity. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2250-2251.	1.5	0
62	Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1508-1515.	3.5	27
63	Azacitidine in Children with Advanced Myelodysplastic Syndrome as a Bridging Treatment Prior to Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S263-S264.	2.0	0
64	Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). <i>Haematologica</i> , 2016, 101, 781-788.	3.5	50
65	Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada. <i>BMC Hematology</i> , 2016, 16, 13.	2.6	20
66	Nutrient Insufficiencies/Deficiencies in Children With Sickle Cell Disease and Its Association With Increased Disease Severity. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1060-1064.	1.5	29
67	Hospitalizations in pediatric patients with immune thrombocytopenia in the United States. <i>Platelets</i> , 2016, 27, 472-478.	2.3	14
68	Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis. <i>British Journal of Cancer</i> , 2016, 114, 623-630.	6.4	47
69	Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinental Collaborative Study. <i>Blood</i> , 2016, 128, 3633-3633.	1.4	15
70	Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 249-249.	1.4	7
71	a Randomized, Double-Blinded, Placebo Controlled Study of IVIG Vs. IVIG with High Dose Methylprednisolone in Rapidly Augmenting Platelet Counts in Childhood ITP. <i>Blood</i> , 2016, 128, 868-868.	1.4	0
72	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. <i>Blood</i> , 2016, 128, 1008-1008.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. <i>Blood</i> , 2016, 128, 4752-4752.	1.4	0
74	The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes. <i>Haematologica</i> , 2015, 100, 633-642.	3.5	26
75	Is the <sc>G</sc>ive <sc>Y</sc>outh a <sc>V</sc>oice questionnaire an appropriate measure of teen&centred care in paediatric oncology: a <sc>R</sc>asch measurement theory analysis. <i>Health Expectations</i> , 2015, 18, 1686-1697.	2.6	3
76	Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2015, 62, 2223-2225.	1.5	18
77	Experience with central venous access devices (<sc>CVAD</sc>s) in the Canadian hemophilia primary prophylaxis study (<sc>CHPS</sc>). <i>Haemophilia</i> , 2015, 21, 469-476.	2.1	13
78	Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes. <i>Journal of Medical Genetics</i> , 2015, 52, 575-584.	3.2	78
79	Thalassaemia in children: from quality of care to quality of life. <i>Archives of Disease in Childhood</i> , 2015, 100, 1051-1057.	1.9	22
80	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	1.4	6
81	Second Line ITP Therapy in the UK: Results from the UK Paediatric ITP Registry. <i>Blood</i> , 2015, 126, 3478-3478.	1.4	0
82	Copy Number Variants Underlying Inherited Bone Marrow Failure Syndromes. <i>Blood</i> , 2015, 126, 2416-2416.	1.4	0
83	Molecular Analysis of Diamond Blackfan Anemia and Genotype-Phenotype Correlation: Experience from the Canadian Inherited Marrow Failure Registry. <i>Blood</i> , 2015, 126, 3621-3621.	1.4	1
84	Validation and reliability of a disease&specific quality of life measure (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td (<sc>T</sc>). <i>Haematology</i> , 2014, 164, 431-437.	2.5	36
85	Caregiving, single parents and cumulative stresses when caring for a child with cancer. <i>Child: Care, Health and Development</i> , 2014, 40, 184-194.	1.7	51
86	Understanding the healthcare experiences of teenaged cancer patients and survivors. <i>Child: Care, Health and Development</i> , 2014, 40, 723-730.	1.7	8
87	Considering quality of life for children with cancer: a systematic review of patient-reported outcome measures and the development of a conceptual model. <i>Quality of Life Research</i> , 2014, 23, 771-789.	3.1	67
88	Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. <i>Blood</i> , 2014, 123, 451-452.	1.4	27
89	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). <i>Blood</i> , 2014, 124, 2867-2871.	1.4	162
90	Pediatric Oncology Clinic Care Model: How to Care for Patients to Achieve Better Continuity of Care in a Medium Sized Program. <i>Blood</i> , 2014, 124, 6000-6000.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS). <i>Blood</i> , 2014, 124, 1328-1328.	1.4	0
92	Risk Factors for Poor Survival after Hematopoietic Stem Cell Transplantation in Inherited Bone Marrow Failure Syndromes. <i>Blood</i> , 2014, 124, 2592-2592.	1.4	0
93	Application of Novel Next Generation Sequencing Gene Panel Assay to Genetic and Clinical Diagnosis of Inherited Bone Marrow Failure Syndromes. <i>Blood</i> , 2014, 124, 257-257.	1.4	0
94	Family-centred care: a qualitative study of Chinese and South Asian immigrant parents' experiences of care in paediatric oncology. <i>Child: Care, Health and Development</i> , 2013, 39, 185-193.	1.7	26
95	Quality of life in immune thrombocytopenia following treatment. <i>Archives of Disease in Childhood</i> , 2013, 98, 895-897.	1.9	17
96	Evaluation of health related quality of life in children with immune thrombocytopenia with the PedsQL <sup>®</sup> 4.0 Generic Core Scales: a study on behalf of the Pays de Loire pediatric hematology network. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 193.	2.4	11
97	Quality of life in childhood immune thrombocytopenia: International validation of the kids' ITP tools. <i>Pediatric Blood and Cancer</i> , 2013, 60, 95-100.	1.5	33
98	Understanding the Importance of Using Patient-Reported Outcome Measures in Patients With Immune Thrombocytopenia. <i>Seminars in Hematology</i> , 2013, 50, S39-S42.	3.4	10
99	Single-Parent Caregivers of Children with Cancer. <i>Journal of Pediatric Oncology Nursing</i> , 2013, 30, 45-55.	1.5	26
100	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. <i>Blood</i> , 2013, 121, 2596-2606.	1.4	179
101	A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). <i>Blood</i> , 2013, 122, 112-123.	1.4	101
102	A survey of the management of newborns with severe hemophilia in Canada. <i>Paediatrics and Child Health</i> , 2013, 18, 189-193.	0.6	3
103	Utility Of The Immature Platelet Fraction In Predicting Recovery With Or Without Treatment In Pediatric Immune Thrombocytopenia. <i>Blood</i> , 2013, 122, 3546-3546.	1.4	1
104	Introducing the Tran QoL: A New Disease-Specific Quality of Life Measure for Children and Adults with Thalassemia Major. <i>Journal of Blood Disorders &amp; Transfusion</i> , 2013, 04, .	0.1	9
105	Characterization Of The Immature Platelet Fraction (IPF) Parameters In Children With Immune Thrombocytopenia. <i>Blood</i> , 2013, 122, 3547-3547.	1.4	1
106	An evidence-based threshold for thrombocytopenia associated with clinically significant bleeding in pediatric intensive care unit patients*. <i>Pediatric Critical Care Medicine</i> , 2012, 13, e316-e322.	0.5	6
107	Understanding the health impact of caregiving: a qualitative study of immigrant parents and single parents of children with cancer. <i>Quality of Life Research</i> , 2012, 21, 1595-1605.	3.1	48
108	A Canadian survey of self-infusion practices in persons with haemophilia A. <i>Haemophilia</i> , 2012, 18, e403-5.	2.1	2

#	ARTICLE	IF	CITATIONS
109	Rasch analysis of the PedsQL: an increased understanding of the properties of a rating scale. <i>Journal of Clinical Epidemiology</i> , 2012, 65, 1117-1123.	5.0	40
110	Impact of caring for a child with cancer on single parents compared with parents from two-parent families. <i>Pediatric Blood and Cancer</i> , 2012, 58, 74-79.	1.5	19
111	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2012, 58, 221-225.	1.5	29
112	Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2012, 58, 395-398.	1.5	41
113	Immigrant to Canada, newcomer to childhood cancer: a qualitative study of challenges faced by immigrant parents. <i>Psycho-Oncology</i> , 2012, 21, 558-562.	2.3	34
114	Communication and language challenges experienced by Chinese and South Asian immigrant parents of children with cancer in Canada: Implications for health services delivery. <i>Pediatric Blood and Cancer</i> , 2012, 58, 572-578.	1.5	47
115	Outcome and Clinical Characteristics of Clonal and Malignant Myeloid Transformation in Inherited Bone Marrow Failure Syndromes. <i>Blood</i> , 2012, 120, 1266-1266.	1.4	0
116	Vitamin D and Zinc Deficiency Associated with Increased Pain Episodes in Children with Sickle Cell Disease. <i>Blood</i> , 2012, 120, 3237-3237.	1.4	3
117	Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation. <i>Clinical Genetics</i> , 2011, 79, 448-458.	2.0	50
118	Identifying determinants of quality of life of children with cancer and childhood cancer survivors: a systematic review. <i>Supportive Care in Cancer</i> , 2011, 19, 1275-1287.	2.2	105
119	Exploring predictors of optimism among parents of children with cancer. <i>Psycho-Oncology</i> , 2011, 20, 411-418.	2.3	29
120	Quality of life during active treatment for pediatric acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , 2011, 128, 1213-1220.	5.1	87
121	Parents of children with cancer: Which factors explain differences in health-related quality of life. <i>International Journal of Cancer</i> , 2011, 129, 1190-1198.	5.1	68
122	Genetic analysis of inherited bone marrow failure syndromes from one prospective, comprehensive and population-based cohort and identification of novel mutations. <i>Journal of Medical Genetics</i> , 2011, 48, 618-628.	3.2	55
123	Fatal Neurotoxicity in a Patient With Down Syndrome Treated With Chemotherapy, Irradiation, Stem Cell Transplant, and Clofarabine. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e111-e113.	0.6	3
124	Health-related quality of life outcomes for patients with immune thrombocytopenic purpura. <i>Annals of Hematology</i> , 2010, 89, 51-54.	1.8	7
125	Evaluating the ability to detect change of health-related quality of life in children with Hodgkin disease. <i>Cancer</i> , 2010, 116, 1608-1614.	4.1	29
126	Nurses provide valuable proxy assessment of the health-related quality of life of children with Hodgkin disease. <i>Cancer</i> , 2010, 116, 1602-1607.	4.1	20



#	ARTICLE	IF	CITATIONS
127	Caregiving Demands in Parents of Children With Cancer: Psychometric Validation of the Care of My Child With Cancer Questionnaire. <i>Journal of Pediatric Nursing</i> , 2010, 25, 258-263.	1.5	11
128	Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.. <i>Blood</i> , 2010, 116, 3681-3681.	1.4	0
129	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. <i>Blood</i> , 2010, 116, 2509-2509.	1.4	0
130	A case of moyamoya syndrome and hemoglobin E/beta $\alpha$ -thalassemia. <i>Pediatric Blood and Cancer</i> , 2009, 52, 422-424.	1.5	15
131	Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura. <i>Pediatric Blood and Cancer</i> , 2009, 53, 652-654.	1.5	51
132	Factors affecting the delivery of family-centered care in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1079-1085.	1.5	24
133	Parental optimism in poor prognosis pediatric cancers. <i>Psycho-Oncology</i> , 2009, 18, 783-788.	2.3	11
134	Evaluating family-centred service in paediatric oncology with the measure of processes of care (MPOC $\alpha$ 20). <i>Child: Care, Health and Development</i> , 2009, 35, 16-22.	1.7	26
135	Identification of paediatric cancer patients with poor quality of life. <i>British Journal of Cancer</i> , 2009, 100, 82-88.	6.4	75
136	Measuring disease-specific quality of life in rare populations: a practical approach to cross-cultural translation. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 92.	2.4	46
137	Iliopsoas hematoma following a bone marrow aspirate. <i>Pediatric Blood and Cancer</i> , 2008, 51, 146-146.	1.5	0
138	Spontaneous remission of myelodysplastic syndrome with monosomy 7 in a young boy. <i>Cancer Genetics and Cytogenetics</i> , 2008, 182, 122-125.	1.0	22
139	Impact of Caring for a Child With Cancer on Parents's Health-Related Quality of Life. <i>Journal of Clinical Oncology</i> , 2008, 26, 5884-5889.	1.6	177
140	Clinical and Genetic Analysis of Unclassifiable Inherited Bone Marrow Failure Syndromes. <i>Pediatrics</i> , 2008, 122, e139-e148.	2.1	49
141	Health-related Quality of Life: Changes in Children Undergoing Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 292-297.	0.6	31
142	Validity, Reliability, and Responsiveness of a New Measure of Health-Related Quality of Life in Children with Immune Thrombocytopenic Purpura: The Kids's ITP Tools. <i>Journal of Pediatrics</i> , 2007, 150, 510-515.e1.	1.8	82
143	Central venous catheter thrombosis as a cause of SVC obstruction and cardiac tamponade in a patient with Diamond-Blackfan anemia and iron overload. <i>Pediatric Blood and Cancer</i> , 2006, 46, 112-114.	1.5	5
144	Disease progression in recently diagnosed patients with inherited marrow failure syndromes: A Canadian inherited marrow failure registry (CIMFR) report. <i>Pediatric Blood and Cancer</i> , 2006, 47, 918-925.	1.5	18

#	ARTICLE	IF	CITATIONS
145	Quantitative Assessment of Drug Treatment Side Effects in Children with Idiopathic Thrombocytopenic Purpura (ITP).. Blood, 2004, 104, 3030-3030.	1.4	3
146	High-Risk Neuroblastoma in Ontario: A Report of Experience From 1989 to 1995. Journal of Pediatric Hematology/Oncology, 2003, 25, 8-13.	0.6	9
147	Using Decision Analysis Techniques to Deal With ???Unanswerable??? Questions in Idiopathic Thrombocytopenic Purpura. Journal of Pediatric Hematology/Oncology, 2003, 25, S62-S63.	0.6	2
148	Acute immune thrombocytopenic purpura: What do we do when things go well?. Paediatrics and Child Health, 2002, 7, 384-385.	0.6	1
149	The diagnosis and treatment of von Willebrand disease in children. Paediatrics and Child Health, 2002, 7, 245-249.	0.6	14
150	Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis. The American Journal of Pediatric Hematology/oncology, 2001, 23, 511-518.	1.3	26
151	â€œLow-Riskâ€•Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia. Journal of Clinical Oncology, 2000, 18, 1012-1012.	1.6	207
152	Randomized Placebo-Controlled Trial of Oral Antibiotics in Pediatric Oncology Patients at Low-Risk With Fever and Neutropenia. The American Journal of Pediatric Hematology/oncology, 2000, 22, 405-411.	1.3	60
153	Neuroblastoma in Down syndrome. , 1999, 33, 125-125.		1
154	Clinical Measures. , 0, , 89-98.		0